CStone doses first patient in CS2009 clinical trial

CStone Pharmaceuticals (HKEX:2616) announced the first patient has been dosed in a global multicenter Phase I clinical trial of CS2009, its independently developed PD-1/VEGF/CTLA-4 trispecific antibody. The trial aims to assess CS2009's clinical potential across various advanced solid tumors, including lung, liver, gastric, endometrial, ovarian, renal, and cervical cancers. CS2009 combines three validated targets to exert multidimensional anti-tumor effects. Preclinical studies demonstrated superior anti-tumor activity compared to potential competitors. The Phase I trial is currently being conducted in Australia, with plans to expand to China and the United States. CStone has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications.